Amgen, AstraZeneca's Tezspire now available in U.S. for severe asthma
AntonioGuillem/iStock via Getty Images         

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN)
announce TEZSPIRE (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S.
TEZSPIRE was approved by the FDA on Dec. 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.